[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100069899":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":42,"centralContacts":46,"locations":51,"responsibleParty":73,"collaborators":25,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":25,"eligibilityCriteria":81,"healthyVolunteers":82,"sex":83,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":25,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":53,"whyStopped":25,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Hadassah Medical Organization","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CYP2C9 substrate: Warfarin, Phenytoin, Losartan, Flurbiprofen, Siponimod.","EXPERIMENTAL","Each participant may be given at least one of the following CYP2C9 substrates: Warfarin, Phenytoin, Losartan, Flurbiprofen and Siponimod.",[13,14,15,16,17,18],"Drug: Warfarin","Drug: Phenytoin","Drug: Losartan & Hydrochlorothiazide","Drug: Flurbiprofen","Drug: Siponimod","Drug: Dicloxacillin",[20,26,29,32,35,38],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Warfarin","Each participant may be given at least one CYP2C9 substrate from the following list: Warfarin, Phenytoin, Losartan, Flurbiprofen and Siponimod.",[9],null,{"type":21,"name":27,"description":23,"armGroupLabels":28,"otherNames":25},"Phenytoin",[9],{"type":21,"name":30,"description":23,"armGroupLabels":31,"otherNames":25},"Losartan & Hydrochlorothiazide",[9],{"type":21,"name":33,"description":23,"armGroupLabels":34,"otherNames":25},"Flurbiprofen",[9],{"type":21,"name":36,"description":23,"armGroupLabels":37,"otherNames":25},"Siponimod",[9],{"type":21,"name":39,"description":40,"armGroupLabels":41,"otherNames":25},"Dicloxacillin","To explore possible effect of dicloxacillin on CYP2C9 activity, some participants will be administered single dose of warfarin and phenytoin before and after intake of dicloxacillin.",[9],[43],{"name":44,"affiliation":5,"role":45},"Yoseph Caraco, MD","PRINCIPAL_INVESTIGATOR",[47],{"name":44,"role":48,"phone":49,"phoneExt":25,"email":50},"CONTACT","00 972 2 6779373","caraco.yoseph@mail.huji.ac.il",[52],{"facility":5,"status":53,"city":54,"state":25,"zip":25,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"RECRUITING","Jerusalem","Israel","IL",{"type":58,"coordinates":59},"Point",[60,61],35.21633,31.76904,{"lat":61,"lon":60},[64,68,72],{"name":65,"role":48,"phone":66,"phoneExt":25,"email":67},"Arik Tzukert, DMD","00 972 2 6776095","arik@hadassah.org.il",{"name":69,"role":48,"phone":70,"phoneExt":25,"email":71},"Hadas Lemberg, PhD","00 972 2 6777572","lhadas@hadassah.org.il",{"name":44,"role":45,"phone":25,"phoneExt":25,"email":25},{"type":74,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100069899","determinants-of-warfarin-metabolism-100069899",false,"NCT00162474","Determinants of Warfarin Metabolism","Correlation Between Phenotypic Activity of CYP2C9 and Genetic Polymorphism in CYP2C9 and Warfarin Metabolism.","Inclusion Criteria:\n\n* Age range of 20-50 years old\n* The absence of significant disease states\n\nExclusion Criteria:\n\n* Known hypersensitivity to warfarin or phenytoin\n* Known hepersensitivity to penicillins or cephalosporins (Dicloxacillin part)\n* The presence of significant disease states\n* Regular use of drugs (including birth control pills)",true,"ALL","20 Years","50 Years",{"count":87,"type":88},1000,"ESTIMATED","INTERVENTIONAL",[91],"NA","The anticoagulant effect of warfarin varies greatly among individuals. Some of this variability is attributed to differences in the activity of CYP2C9, the predominant enzyme involved in the metabolism of S-warfarin.\n\nThe present study is designed to define the differences in warfarin metabolism among healthy individuals carrying different CYP2C9 genotypes. In addition, the study will define the correlation between the phenytoin metabolic ratio, a marker of CYP2C9 activity in vivo, and warfarin metabolism.",[94],"Healthy",[96],"Healthy Volunteers","2026-04-16",{"date":99,"type":100},"2026-04-21","ACTUAL",{"date":102,"type":100},"2003-09",{"date":104,"type":88},"2030-12",{"name":5,"class":6},1]